Grahame Woollam is an Associate Director of Science & Technology in Novartis Pharma AG, Switzerland. He is a Materials Science Project Leader working at the interface of drug substance and drug product development. Grahame is accountable for implementing and evolving modelling tools related to physical form and process risk profiling, with a focus on operationalising Crystal Structure Prediction.
His PhD focused on the crystallisation of polymorphs and multicomponent systems under the supervision of Professor Roger J. Davey. He has nineteen years’ industrial experience spanning GSK and Novartis, working on solid form design and crystallisation process development.
Numerous small molecule patents name him as inventor, he has published on molecular salts, cocrystallisation and analysing ab initio crystal structure landscapes to inform on polymorphism risk.
Research interests include “crystallisability” in the pursuit of engineering organic materials via structure-process-property relationships. This entails measuring and modelling nucleation and crystal growth of pharmaceutical compounds. Grahame is a Fellow of the Royal Society of Chemistry, an elected committee member of the RSC Solid State Chemistry Group, RSC Statistical Mechanics & Thermodynamics Group and vice-chair of the British Association for Crystal Growth.